1. Pink Sheet

Mallinckrodt's Opioid Resolution Through Generic Unit Bankruptcy May Be 'Test Case'

 
• By Brenda Sandburg

Mallinckrodt to pay $1.6bn and place its generics unit in bankruptcy under agreement in principle for US global settlement; six states are not on board, including New York, whose suit is still set to go to trial March 20.

Opioid Law Concept 3D Illustration
Mallinckrodt reaches agreement in principle with MDL plaintiffs' executive committee to resolve opioid litigation

Mallinckrodt PLC is seeking to free itself of opioid litigation by putting its generic unit into Chapter 11 bankruptcy and then paying plaintiffs $1.6bn over eight years through a trust overseen by the bankruptcy court.

A "channeling injunction" is expected to release parent Mallinckrodt from all opioid-related claims that could have been asserted against it and its subsidiaries before the bankruptcy plan becomes

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legal & IP

More from Pink Sheet

Recent and Upcoming FDA Advisory Committee Meetings

 
• By Sue Sutter

Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.

UK Health Data Research Service Looks ‘Encouraging’ For Industry, But Implementation Details Will Be Key

 
• By Anabel Costa-Ferreira

Marcus Vass and Vladimir Murovec of international law firm Osborne Clarke tell the Pink Sheet what the government's planned HDRS might mean for industry, and how it compares with the European Health Data Space.

EU Health Data Space May Speed Up R&D Through Access To Multi-Omics & Clinical Record Data

 
• By Eliza Slawther

The European Health Data Space framework will allow companies to accelerate R&D processes and identify new molecular targets faster by facilitating centralized access to certain types of high-quality data, Finland’s Orion Pharma says.